ReviewCell insight2026
Regulation of cellular functions and diseases by the MARCH E3 ubiquitin ligases.
Review in Cell insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The membrane-associated RING-CH (MARCH) family is a type of membrane-localized E3 ubiquitin ligase, which catalyze substrate ubiquitination via their characteristic RING-CH domains. MARCH proteins target their substrates for polyubiquitination of different linkage types and degradation via distinct routes. This review outlines recent advancements about the structural features, subcellular localizations, expression profiles of MARCH proteins and their roles in regulation of physiological processes and diseases, such as immune response, organelle homeostasis and tumorigenesis. Future studies would identify additional targets of the MARCH family and reveal the regulatory networks of MARCH family on substrates, offering an opportunity to target the MARCH family for development of drugs against severe human diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.